Ignyta (RXDX) Receiving Somewhat Positive News Coverage, Report Shows
Media stories about Ignyta (NASDAQ:RXDX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ignyta earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.0313447981247 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Ignyta (NASDAQ RXDX) opened at $15.55 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.07 and a quick ratio of 6.07. Ignyta has a 1-year low of $4.60 and a 1-year high of $18.30.
Ignyta (NASDAQ:RXDX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.03. equities research analysts expect that Ignyta will post -2.27 earnings per share for the current year.
A number of research analysts recently issued reports on the stock. SunTrust Banks assumed coverage on shares of Ignyta in a research note on Monday, November 20th. They issued a “buy” rating for the company. Cantor Fitzgerald set a $23.00 price target on shares of Ignyta and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Zacks Investment Research upgraded shares of Ignyta from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Tuesday, November 14th. Ladenburg Thalmann Financial Services raised their price objective on shares of Ignyta from $20.25 to $31.00 in a report on Wednesday, October 18th. Finally, J P Morgan Chase & Co reissued a “buy” rating and set a $20.00 price objective (up previously from $18.00) on shares of Ignyta in a report on Thursday, October 12th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ignyta presently has an average rating of “Buy” and a consensus price target of $23.80.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/ignyta-rxdx-receiving-somewhat-positive-news-coverage-report-shows/1760311.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with Analyst Ratings Network's FREE daily email newsletter.